Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myovant Sciences Ltd (NY: MYOV )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Mar 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myovant Sciences Ltd

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
FDA Accepts Myovant Sciences and Pfizer's Filing For Review In Uterine Fibroids
Myovant Sciences (NASDAQ: MYOV) and Pfizer (NASDAQ: PFE) received U.S. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022). Urovant is a wholly-owned... 
Via Benzinga
Myovant Sciences: Q4 Earnings Insights
Myovant Sciences (NYSE:MYOV) reported its Q4 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer
Via Benzinga
Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe
Via Benzinga
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: Myovant Sciences
Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Myovant... 
Via Benzinga
U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months
The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc. 
Via Benzinga
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12
SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00. Shares of Myovant Sciences are trading up 8.08% over the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Dow, Nasdaq Up Triple Digits as Wall Street Bets on Inflation's Top
Despite a slightly hotter-than-expected March consumer price index (CPI) reading earlier today, stocks are moving higher, as Wall Street bets on inflation's peak. 
Via Talk Markets
Myovant Sciences Collapses As FDA Holdup Snags Its Blockbuster Potential
The Pfizer-partnered endometriosis drug is facing additional FDA scrutiny. 
Via Investor's Business Daily
What's Going On With Myovant Sciences Stock Today?
Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New... 
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Urovant Reports Publication of New Efficacy, Safety Data On Gemtesa For Overactive Bladder
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd, announced the  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Surgalign Holdings (NASDAQ:SRGA) ... 
Via Benzinga
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
Myovant Sciences's Return on Invested Capital Insights
Myovant Sciences (NYSE:MYOV) brought in sales totaling $54.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 193.85%, resulting in a... 
Via Benzinga
Myovant Sciences: Q3 Earnings Insights
Myovant Sciences (NYSE:MYOV) reported its Q3 earnings results on Wednesday, January 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For January 26, 2022
Companies Reporting Before The Bell • Blue Foundry (NASDAQ:BLFY) is projected to report earnings for its fourth quarter. • First BanCorp (NYSE:FBP) is likely to... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.